GW Pharmaceuticals Plc. is a biopharmaceutical company that discovers, develops, and commercializes cannabinoid prescription medicines. Since May 10, 2013, the stock price has climbed 1,033%.
Clinical-stage cannabinoid-based drug developer Zynerba Pharmaceuticals (NASDAQ:ZYNE) had been one of the strongest-performing pot stocks over the trailing year prior to the start of this past week.
If you look around, chances are you won’t find many marijuana stocks struggling. But there’s always an outlier — and for the marijuana industry that’s drugmaker Insys Therapeutics.
When GW Pharmaceuticals announced its fiscal third-quarter results on Monday, the company provided plenty of information about its performance during the quarter. However, it wasn’t any of the numbers in the update that caused this decline. Instead, one word caused investors’ disappointment.
For many weed stocks, the summer of 2017 hasn’t been what you’d call a scorcher. However, three marijuana stocks have sizzled this summer.
If just a single clinical trial works in favor of Cara Therapeutics, it could regain everything it’s recently lost and possibly hit a $1 billion market cap.
Identifying companies in great financial health is important when investing in an industry like marijuana. That being said, the Canadian marijuana stocks on our list all have current ratios of at least 10x, and debt to equity ratios under 20%.
In mid-June home lawn and fertilizer care specialist The Scotts Miracle-Gro Company (NYSE:SMG) lowered its full-year fiscal 2017 outlook, citing a more than 10% drop in mass retail sales compared to the year-to-date checkpoint from the previous year. That was caused by challenging weather this spring in core markets across the United States.
The Creso Pharma Ltd (ASX: CPH) share price has been amongst the biggest movers on the market this morning. This morning the company revealed that it plans to expand into the Canadian market.
Over the trailing-12-month period through July 15, the average marijuana stock with a market cap in excess of $200 million — a dozen stocks in total, which excluded MedReleaf because it just went public a month ago — was up by 332%.
The Canadian government is moving quickly to legalize marijuana and, unlike the patchwork state-by-state approach unfolding in the U.S., Canada is set to make it legal nationwide by this time next year.
In total, four marijuana stocks jumped higher by at least 10% last week. Let’s take a brief look at some of these moves.
Few stocks have skyrocketed like Axim Biotechnologies. Last year, Axim ranked not only as the best marijuana stock in terms of overall performance, but also took the top spot among all biotech stocks.
Well, we have news for Canadian marijuana stock investors: There’s a new threat on the horizon, at least for our neighbors to the north.
There are three different general types of marijuana stocks on the market. Some are marijuana growers. Others provide supplies to marijuana growers. Then there’s the third type: the biotechs. Zynerba Pharmaceuticals belongs to the last kind of marijuana stock.
Only 51 authorized licenses have been given to suppliers of medical marijuana in Canada. Canopy Growth Corporation holds four of them.
On June 27, Cara Therapeutics (NASDAQ:CARA), a clinical-stage biotech company with a focus on treating chronic pain and pruritus, surged to an all-time intraday high of $28.50 a share. Cara was just $73 million away from joining the $1 billon market cap ranks.
There have been two interesting developments with marijuana producers Aurora Cannabis Inc. (TSXV:ACB) and Aphria Inc. (TSX:APH).
Since Justin Trudeau’s election, the Canadian cannabis space has seen significant growth both in public and private sectors. The industry is gearing up for its entry into the legal recreational cannabis market set to open up by July 1, 2018.
Insys Therapeutics is one of several biotechs developing cannabinoid drugs. Unlike most of these other companies, though, Insys has already won regulatory approval for its first cannabinoid — Syndros.
The results for Canopy Growth’s stock have been terrific so far, yielding a return of over 152% since inception. The stock has been performing well despite lacklustre results and frequent losses.
The Auscann Group Holdings Ltd share price has continued its strong run and is up a further 6% to 46 cents today. Why has it jumped? Let’s look to find out.
MedReleaf is one of less than four dozen licensed producers and retailers of medical cannabis products in Canada. The company was founded just four years ago, and it focuses on supplying dried cannabis, cannabis oils, and cannabis oil capsules to qualified medical patients in Canada.
If these headsets make ordering marijuana easier, which would in turn increase sales, this technology will be another boon for marijuana dispensary stocks.
Aurora Cannabis Inc. today is one of the pre-eminent marijuana producers listed on the TSX Venture Exchange with a market capitalization just shy of $750 million, making it the fourth-largest marijuana stock behind only GW Pharmaceuticals PLC- ADR, Canopy Growth Corp., and Aphria Inc.
Here’s why Scotts Miracle-Gro Company, GW Pharmaceuticals, and Canopy Growth Corporation are three stocks to buy if you’ve never bought a cannabis stock.
Unlike GW Pharmaceuticals and Zynerba Pharmaceuticals, which rely on cannabinoid-based medicines to fill out the entirety of their drug-development pipelines, Arena Pharmaceuticals is one of the drug developers that have some of their pipelines devoted to cannabinoid-type therapeutics or CB agonists and other portions devoted to non-cannabinoid medicines.
Warren Buffett is well known as the most successful investor of all time. Buffett spent his formative years under the tutelage of Benjamin Graham, who is known today as the “father of value investing.” Let’s see whether or not Aphria Inc. can pass Buffett’s mentor’s criteriea test.
Shares of Cara Therapeutics Inc., a clinical-stage biotech company with a focus on treating pain and pruritus, rocketed higher by as much as 11% during Wednesday’s trading session after providing an update to its phase 3 trial involving kappa opioid receptor agonist CR845.
Though there are a number of direct players in the industry, some of the most surprising growth can be seen in emerging industry players. One such name is Scotts Miracle-Gro.
On July 1, 2017, Nevada will legalize the use and sale of recreational marijuana, which could be a catalyst for long-term gains for three cannabis stocks.
The industry and the Canopy Growth Corp. were going to be the next big thing for investors, but things have cooled down gradually over the past few months.
According to a press release from Health Canada in late May, big changes are coming to the country’s medical cannabis program.
The first cannabis stock ETF of its kind, the Horizons Marijuana Life Sciences Index ETF allows investors to own more than a dozen pot stocks through a single investment fund. Today, however, is a different story.
Medical Marijuana, Inc. holds the distinction of being the first publicly listed marijuana stock, and its diversity is rare, but is it worth investing in?
Thanks to a 2% gain to 49 cents today, the Cann Group Ltd (ASX: CAN) share price has now risen over 63% since hitting the ASX boards.
In late May, MedReleaf priced its public offering at just over $7 per share. The marijuana stock IPO raised a whopping $75 million. Unfortunately, things didn’t work out as planned for pot investors or MedReleaf.
Here is a novel concept could increase the safety of cannabis deliveries and be a boon for marijuana stocks: drone deliveries. Not only will drone deliveries increase safety, but they will also make delivery faster and more convenient.
MedReleaf Corp. is the latest cannabis stock to hit the TSX. Could they be the spark to reignite the second wave of the green rush?
Aurora Cannabis Inc. has just announced another possible acquisition, and this time snatching up one of the world’s largest industrial hemp producers.
In April, investors were privy to the very first marijuana stock ETF, which debuted on the Toronto Stock Exchange with slightly more than a dozen holdings. This represented the very first time a basket fund was created for investors to easily diversify their pot-stock holdings. And last week, investors witnessed another marijuana first: the largest North American marijuana stock IPO of all-time.
The threat of increasing competition for GW Pharmaceuticals’ promising epilepsy drug took a toll on investors’ confidence last month.
Oh, how the mighty have fallen. Shares of Canopy Growth Corp. have dropped by over $6 a share, or 47.5%, since the middle of February.
There is so much Canadian cannabis investment money right now that it is cascading down into the United States and Canadian investors are easily outbidding domestic acquirers.
Canadian marijuana stocks have been on a punishing slide for three straight months despite a temporary blip of investor fever in April that sent share prices soaring to record highs as Ottawa tabled legislation to legalize pot.
In the red-hot world of marijuana stocks, there can be no question that GW Pharmaceuticals reigns supreme, but could small-cap biotech Zogenix be a threat?
It is apparent that Aphria Inc. will be one of the major winners among marijuana companies. The timing of when to buy shares might be a bit tougher, though.
If there is a “Holy Grail” milestone out there for cannabis stocks, it’s the $1 billion sales mark. The first cannabis company to hit $1 billion in sales will likely validate the industry to Wall Street and investors. But which marijuana stock has the best chance at being first to $1 billion in annual sales?
On June 1, 2017, High Times announced that controlling interest in the company had been acquired by 20 investors, a group comprised of cannabis industry members, entrepreneurs and entertainment veterans. Oreva Capital, a Los Angeles-based investment firm, led the High Times acquisition, valuing the company at $70 million. The company will now operate as High Times Holding Company.
How about another cannabis company to spark up your interest? Newstrike Ltd. is Canada’s newest pot stock that will be hitting the TSX Venture Exchange this Thursday.